Chronic Fatigue Syndrome: The Current Status and Future Potentials of Emerging Biomarkers.
Chronic Fatigue Syndrome: The Current Status and Future Potentials of Emerging Biomarkers.
复制标题
DOI：
10.1080/21641846.2014.906066
复制
发表时间：
2014-06-01
期刊：
影响因子：
--
通讯作者：
Dimitrakoff JD
中科院分区：
文献类型：
--
作者：
Fischer DB;William AH;Strauss AC;Unger ER;Jason L;Marshall GD Jr;Dimitrakoff JD
慢性疲劳综合征(CFS)仍然是一种不完全具有特征性的疾病，部分原因是对其定义、生物学基础和诊断存在争议。生物标记物是一种客观指标，通过提供一种更连贯一致的方法来研究、诊断和治疗疾病，可能会改善我们对CFS的理解。这样的指标可能使我们能够区分CFS亚型--每种亚型都由特征生物标记物定义--目前被合并在CFS的单一、异质性条件下。反过来，这些描述可能会根据对疾病更准确的描述来指导更细粒度、更有针对性和有针对性的治疗策略。在这里，我们综述与疾病的神经和免疫成分相关的潜在的CFS生物标记物，并讨论如何利用这些生物标记物来推动CFS领域的发展，强调临床应用和未来研究的潜在路线。
Chronic fatigue syndrome (CFS) remains an incompletely characterized illness, in part due to controversy regarding its definition, biological basis and diagnosis. Biomarkers are objective measures that may lead to improvements in our understanding of CFS by providing a more coherent and consistent approach to study, diagnosis and treatment of the illness. Such metrics may allow us to distinguish between CFS subtypes – each defined by characteristic biomarkers – currently conflated under the single, heterogeneous condition of CFS. These delineations, in turn, may guide more granular, focused, and targeted treatment strategies based on more precise characterizations of the illness. Here, we review potential CFS biomarkers related to neurological and immunological components of the illness, and discuss how these biomarkers may be used to move the field of CFS forward, emphasizing clinical utility and potential routes of future research.